探索甲福明对皮病的保护作用:从队列研究和遗传学的见解
Yanyan Hu1, Shan Lu2, Cheng Xue1
1Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Journal of translational medicine
|March 22, 2025
概括
在患有2型糖尿病的老年患者中,甲福明可能会降低肉症的风险. 该研究确定了GDF15作为肉症的潜在治疗标.
科学领域:
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 在老年人群中,萨科佩尼亚是一个越来越令人担忧的问题,特别是在2型糖尿病患者中.
- 梅特福林 (一种常见的糖尿病药物) 对萨尔科佩尼亚的潜在益处尚不清楚.
研究的目的:
- 研究2型糖尿病的老年患者使用甲福明与肉症风险之间的关联.
- 通过使用遗传和分子方法,探索萨尔科佩尼亚的潜在药物标.
主要方法:
- 对国家健康和营养检查调查 (NHANES) 数据 (n=3549) 的分析,以评估甲素与肉症的关联.
- 使用大型全基因组关联研究 (GWAS) 数据集 (英国生物银行和FinnGen) 来确定因果关系的门德尔随机化 (MR) 分析.
- 分子对接,以调查甲胺与已识别的药物点之间的相互作用.
主要成果:
- 甲胺使用与改善握力和骨肌肉质量以及降低死亡率有关.
- 门德尔的随机化分析表明,GDF15基因表达和肉症特征之间存在因果关系.
- 分子对接证实了甲胺与GDF15的稳定结合15.
结论:
- 在患有2型糖尿病的老年患者中,甲福明可能会对缩症产生保护作用.
- GDF15成为开发新型萨尔科佩尼亚治疗的潜在治疗标.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Hypoglycemia and Glucagon
146
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
146
Overview of Carbohydrate Metabolism
630
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
630
Oral Hypoglycemic Agents: Glinides
120
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
120
Dipeptidyl Peptidase 4 Inhibitors
148
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
148


